German scientists have presented a dual modification strategy that combines CRISPR-Cas9 and CAR technology to enhance the efficacy of natural killer...

Last week, Vor Bio announced new, encouraging clinical data from the ongoing Phase 1/2 VBP101 trial of trem-cel followed by the anti-CD33...

A CRISPR-based screen has revealed that the transcription factor ZNF740 plays a pivotal role in determining the sensitivity of acute myeloid leukaemia...

AvenCell Therapeutics recently announced that the first patient has been dosed in a Phase 1A study with its lead product candidate AVC-201. This novel...

As 2023 draws to a close, we look back on some of the major clinical highlights from the year gone by.

In this article, we look at recent clinical updates from the gene-editing field. These updates include clinical data from Vor Bio's ongoing Phase 1/2a...

Leading epigeneticist Gabriella Ficz has used CRISPR technology to investigate the interplay between DNA methylation and cancer. Her latest findings...

Beam Therapeutics reports dosing of the first patient with BEAM-201, a multiplex-edited allogeneic CAR-T cell candidate developed to treat relapsed or...